Posts Categorized: MS News

Brain ageing has been reversed for the first time – offering hope of cure for Alzheimer’s disease & multiple sclerosis

Source The London Economic: The groundbreaking feat was achieved by destroying a protein that stiffens the organ – much like muscles and joints. Brain ageing has been reversed for the first time, offering hope of a cure for Alzheimer’s disease and multiple sclerosis, say British scientists. The groundbreaking feat was achieved by destroying a protein that… Read more »

Lack of residential care for younger people with disability

Source ITV: Nina, 46, is housed in an old people’s home. he’s just 46 years old. But Nina Thair has been housed in an old people’s home in Sussex. She has multiple sclerosis – and her local council says there is nowhere else suitable for her. Nina’s problem – the council’s problem – is that the… Read more »

NICE rejects Sativex in draft guidance on cannabis-based medicinal products

Source MS Trust: Draft guidance published today on August 8 does not recommend Sativex as a treatment for MS spasticity because it is not a cost-effective treatment. In November 2018, the legal status of cannabis was amended to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need. To support this change, NICE (National Institute for Health and Care Excellence) has reviewed… Read more »

The MS Trust have launched a new pack to help teachers and pupils raise awareness of MS and dispel some common myths and misunderstandings

Source MS Trust: MS Trust supporter Jenna Chudasama teaches at a secondary school in Leicester and recently used the pack to deliver an assembly to students about her own MS experience. “I hope that I inspired others to live their life to the full, no matter what challenges they are faced with,” Jenna tells us. I… Read more »

Grant from MS Society, Parkinson’s UK to Establish Digital Brain Bank

Source Parkinson’s News Today: The Multiple Sclerosis (MS) and Parkinson’s Tissue Bank at Imperial College London, is the largest repository of brain and spinal cord tissue samples in Europe. Now, the MS Society and Parkinson’s UK has announced a £3 million grant (about $3.6 million) to support its transition into a digital brain bank powered by a virtual reality platform, which will provide… Read more »

Research request from Kings College London

Source Kings College London: “I am a third-year psychology student at King’s College London, currently assisting a PhD student, Jowinn Chew (cc’d in this email), on her research supervised by Dr Colette Hirsch and Prof Rona Moss-Morris from the Health Psychology Department. The research is focusing on identifying the cognitive mechanisms which underpin and maintain… Read more »

Early MS scans ‘can predict long-term prognosis’

Source BBC: Scans carried out when someone is first diagnosed with multiple sclerosis can predict their long-term prognosis, research has shown. Magnetic resonance imaging (MRI) scans are already a key part of the diagnosis and management of MS. But a 15-year study of people with clinically isolated syndrome (CIS), who can go on to develop MS,… Read more »

MS: Drugs trial hope for multiple sclerosis patients

Source BBC:  Welsh patients are taking part in a drugs trial aimed at slowing late-stage multiple sclerosis progression. Experts are looking at how effective a drug is after a smaller study found it may slow down neuronal degeneration. Euryl James, of Llangennith, Gower, said she got involved as a breakthrough could be life-changing. A total… Read more »

EMA warns that Gilenya must not be taken during pregnancy.

Source MS Trust: The European Medicines Agency (EMA) has recommended that Gilenya (fingolimod) must not be taken by pregnant women or women of childbearing age who are not using effective contraception. A review of Gilenya and pregnancy was carried out by the EMA’s safety committee following reports which suggested that babies born to mothers taking Gilenya during pregnancy have… Read more »

Phase 1 Trial of T20K, Plant Protein-derived Therapy for MS, Doses 1st Group of Healthy Men

Source Multiple Sclerosis News Today: A first group of healthy volunteers in a Phase 1 trial assessing the safety and tolerability of T20K, Cyxone‘s plant protein-derived candidate for the treatment of multiple sclerosis(MS), has been dosed in a study taking place in The Netherlands, the company announced. T20K is an investigational prophylactic (preventive) therapy, possibly intended for all MS… Read more »